130 related articles for article (PubMed ID: 35063220)
1. Low iodine diet advice and differentiated thyroid cancer treatment: A historic exploration in three UK centres.
England C; Ingarfield-Herbert K; Beasley M; Moss L; Vinjamuri S; Haupt-Schott I; McKane G; Hunt L; Herbert G; Leary S; Ness A; Atkinson C
Clin Nutr ESPEN; 2022 Feb; 47():315-320. PubMed ID: 35063220
[TBL] [Abstract][Full Text] [Related]
2. A Survey of UK Centres on Low Iodine Diet Recommendations prior to Radioiodine Ablation Therapy for Differentiated Thyroid Cancer.
England CY; Moss L; Beasley M; Haupt-Schott I; Herbert G; Atkinson C
Eur Thyroid J; 2020 May; 9(3):132-138. PubMed ID: 32523889
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
4. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas.
Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
Thyroid; 2014 Aug; 24(8):1289-96. PubMed ID: 24731156
[TBL] [Abstract][Full Text] [Related]
5. Experiences of low iodine diets in the treatment of differentiated thyroid cancer with radioactive iodine ablation therapy.
Herbert G; Searle A; England CY; Ness A; Beasley M; Haupt-Schott I; Moss L; Wescott J; Atkinson C
Clin Nutr ESPEN; 2020 Oct; 39():190-197. PubMed ID: 32859315
[TBL] [Abstract][Full Text] [Related]
6. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
7. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine remnant ablation: current indications and dosing regimens.
Haugen BR
Endocr Pract; 2012; 18(4):604-10. PubMed ID: 22849876
[TBL] [Abstract][Full Text] [Related]
9. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma.
Morris LF; Wilder MS; Waxman AD; Braunstein GD
Thyroid; 2001 Aug; 11(8):749-55. PubMed ID: 11525267
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
11. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.
Lamartina L; Durante C; Filetti S; Cooper DS
J Clin Endocrinol Metab; 2015 May; 100(5):1748-61. PubMed ID: 25679996
[TBL] [Abstract][Full Text] [Related]
12. Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
Park SY; Kim HI; Choi JY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn SH; Kim K; Jeong JG; Kim SW; Chung JH; Kim TH
Oral Oncol; 2018 Sep; 84():41-45. PubMed ID: 30115474
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer.
Ito S; Iwano S; Kato K; Naganawa S
Ann Nucl Med; 2018 Jul; 32(6):418-424. PubMed ID: 29766463
[TBL] [Abstract][Full Text] [Related]
14. Low iodine diet in differentiated thyroid cancer: a review.
Li JH; He ZH; Bansal V; Hennessey JV
Clin Endocrinol (Oxf); 2016 Jan; 84(1):3-12. PubMed ID: 26118628
[TBL] [Abstract][Full Text] [Related]
15. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
[TBL] [Abstract][Full Text] [Related]
16. Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment.
Abelleira E; Peñaloza MA; Jerkovich F; Bueno F; Pitoia F
Arch Endocrinol Metab; 2021 Nov; 65(3):315-321. PubMed ID: 34731559
[TBL] [Abstract][Full Text] [Related]
17. Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
Forleo R; Fralassi N; Maino F; Capezzone M; Brilli L; Pilli T; Cantara S; Castagna MG
J Endocrinol Invest; 2021 Jan; 44(1):139-144. PubMed ID: 32388842
[TBL] [Abstract][Full Text] [Related]
18. Impact of low iodine diets on ablation success in differentiated thyroid cancer: A mixed-methods systematic review and meta-analysis.
Herbert G; England C; Perry R; Whitmarsh A; Moore T; Searle A; Chotaliya S; Ness A; Beasley M; Atkinson C
Clin Endocrinol (Oxf); 2022 Dec; 97(6):702-729. PubMed ID: 35484696
[TBL] [Abstract][Full Text] [Related]
19. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
20. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
